Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by AmericanInvon Mar 26, 2011 5:00pm
195 Views
Post# 18345583

Great Quarter!

Great Quarter!So it seems they announced that they lost
.03 per share, which is great news.  On September 30 the year to date loss was
.14/share, which means that they made
.11/share in Q4.  This was the first quarter without US operations and without any GM involvement, so this could be said to be their first normal quarter.  They also said they had $10MM of cash.  If you run the math:
.11/share per quarter  *  4 quarters = ~
.44/share per year (assuming no growth)
$10MM cash / 20 MM shares = ~
.50/share of cash
Apply a 4.0x multiple to EPS and add cash ->              4 *
.44 +
.50 = $2.26
Apply a 6.0x multiple to EPS and add cash ->              6*
.44 +
.50 = $2.70
Current trading price is
.96.  Should be trading in the $2- $3 range at a minimum, but more reasonably at $4 - $5 if you factor in the growth at Ford and the US automotive industry that is expected.
Anyone have any commments?
American Investor
Bullboard Posts